Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
Andrew Zolopa(Palo Alto University), Andrew Cheng(Gilead Sciences (United States)), Jeffrey Enejosa(Gilead Sciences (United States)), Brian P. Kearney(Belfast Health and Social Care Trust), Lijie Zhong(Gilead Sciences (United States)), Daniel S Berger(University of Illinois Chicago), Steven L. Chuck(Gilead Sciences (United States)), Harry Lampiris(San Francisco VA Medical Center)
Cited by 114
Related Papers
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
|AIDS|2000|1k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801